A 68-year-old female patient with myelofibrosis was admitted for scheduled matched unrelated donor allogeneic hematopoietic stem cell transplant for the treatment of myelofibrosis. Her past medical history was also significant for Grover disease, also known as transient acantholytic dermatosis, characterized by chronic pruritic skin eruptions. On admission, the patient had no complaints with stable vital signs and benign physical examination. Laboratory values were notable for anemia with hemoglobin of 8.33g/dL, white blood cell count of 7.22 k/uL, and platelet count of 297 k/uL. Upon admission, the patient received conditioning chemotherapy with melphalan and flucytosine followed by stem cell transplant on hospitalization day 5. Graft-versus-host disease prophylaxis consisted of post-transplant cyclophosphamide, tacrolimus, and mycophenolate. In terms of antimicrobial agents, prophylactic acyclovir was initiated on admission. Both ciprofloxacin and micafungin were initiated on post-transplant day 4 at the onset of severe neutropenia (absolute neutrophil count of 380 cells/uL). Micafungin was transitioned to oral voriconazole 200 mg twice daily on post-transplant day 6.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Epidemiology and outcome of zygomycosis: a review of 929 reported cases.Clin Infect Dis. 2005; 41: 634-653
- Zygomycetes in human disease.Clin Microbiol Rev. 2000; 13: 236-301
- Outbreaks of mucorales and the species involved.Mycopathologia. 2020; 185: 765-781
- Epidemiology and clinical manifestations of mucormycosis.Clin Infect Dis. 2012; 54: S23-S34
- Global cutaneous mucormycosis: a systematic review.J Fungi (Basel). 2022; 8: 194
- Infections due to emerging and uncommon medically important fungal pathogens.Clin Microbiol Infect. 2004; 10: 48-66
- Challenges in the diagnosis and treatment of mucormycosis.Med Mycol. 2018; 56: 93-101
- Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis).Clin Infect Dis. 2012; 54: S55-S60
- Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.Lancet Infect Dis. 2019; 19: e405-ee21
- Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis.J Antimicrob Chemother. 2021; 76: 2636-2639
Published online: September 20, 2022Uma Paniker, MD, Section Editor
Conflicts of Interest: None.
Authorship: All authors had access to the data and a role in writing this manuscript.
© 2022 Elsevier Inc. All rights reserved.